Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218231

SCHEMBL23218231

SCHEMBL23218231

NCc1cccc(-c2coc3ccc(COc4ccccc4CC(=O)O)cc23)c1

nearest known ligand 0.70

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CFD P00746 17/20 0.70
▸ F11 P03951 7/20 0.70
▸ TPSB2 P20231 6/20 0.70
▸ KLKB1 P03952 2/20 0.70
▸ PLAU P00749 2/20 0.70
▸ PLG P00747 1/20 0.70
▸ F7 P08709 1/20 0.70
▸ PTGER1 P34995 1/20 0.52
▸ PTGER4 P35408 1/20 0.52
▸ PTGER3 P43115 1/20 0.52
▸ PTGER2 P43116 1/20 0.52
▸ FFAR1 O14842 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29591507 1.00 CFD (0.70) CFDF11TPSB2KLKB1PLAU
SCHEMBL23228984 0.90 CFD (0.56) CFDF11TPSB2KLKB1PLAU
SCHEMBL23218957 0.88 CFD (0.54) CFDF11TPSB2KLKB1PLAU
SCHEMBL29853152 0.88 CFD (0.54) CFDF11TPSB2KLKB1PLAU
SCHEMBL23219221 0.85 CFD (0.68) CFDF11TPSB2KLKB1PLAU
SCHEMBL29593248 0.85 CFD (0.68) CFDF11TPSB2KLKB1PLAU
SCHEMBL23218477 0.85 CFD (0.70) CFDF11TPSB2KLKB1PLAU
SCHEMBL29592336 0.85 CFD (0.70) CFDF11TPSB2KLKB1PLAU
SCHEMBL16397008 0.84 CFD (1.00) CFDF11TPSB2KLKB1PLAU
SCHEMBL23218110 0.83 CFD (0.74) CFDF11TPSB2KLKB1PLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 — — EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
US-20160361275-A1 SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY ACADIA PHARMACEUTICALS INC. 2016-12-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160361275-A1 SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY SLC6A4, HTR4, GPR34 CFD 4300/4885F11 3972/4885TPSB2 1052/4885
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885F11 24/4885TPSB2 419/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885F11 14/4885TPSB2 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.